

This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Cancer				
Cancer	CD70 (CD27L); CD27	<p>Studies in mice suggest that CD70-expressing dendritic cell (DC)-based vaccines could improve cancer treatment. Immature mouse DCs expressing <i>CD70</i> were loaded with an ovalbumin peptide and adoptively transferred to healthy mice. Wild-type mice expressing the CD70 receptor CD27 had greater expansion of antigen-specific CD8⁺ T cells and better CD8⁺ T cell memory than CD27-deficient controls. In mice with melanoma tumors engineered to express ovalbumin peptide, the CD70-expressing DCs decreased tumor growth in CD27-expressing mice compared with that seen in CD27-deficient controls. Future studies could include evaluating the vaccine strategy in other models of cancer and examining its potential effects on regulatory T cells.</p> <p>SciBX 2(13); doi:10.1038/scibx.2009.524 Published online April 2, 2009</p>	Patent and licensing status undisclosed	<p>Keller, A. <i>et al. Blood</i>; published online March 11, 2009; doi:10.1182/blood-2008-03-148007 Contact: Jannie Borst, The Netherlands Cancer Institute, Amsterdam, the Netherlands e-mail: j.borst@nki.nl</p>